nivolumab and hyaluronidase (Opdivo subcutaneous): FDA status

No recent update Indication: All approved solid tumor indications including urothelial and renal cell carcinoma.

Regulatory history

• May 7, 2024: FDA accepted for review. FDA accepted BLA for subcutaneous nivolumab formulation for all currently approved solid tumor indications. Urology Times

All products in the FDA Tracker